NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $18.21 +0.05 (+0.28%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$17.88▼$18.9250-Day Range$17.60▼$24.5152-Week Range$10.21▼$31.50Volume4.65 million shsAverage Volume3.70 million shsMarket Capitalization$4.35 billionP/E Ratio21.42Dividend YieldN/APrice Target$27.67Consensus RatingBuy Company OverviewADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More… ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 81% of companies evaluated by MarketBeat, and ranked 208th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 1 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth35.29% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 35.29% in the coming year, from $0.51 to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 21.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.90.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 21.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 12.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.99% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 3.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.99% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 3.49%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.73 News SentimentADMA Biologics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for ADMA Biologics this week, compared to 9 articles on an average week.Search InterestOnly 15 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows25 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 47% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,644,269.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms Sells 92,941 SharesJune 18, 2025 | insidertrades.comInsider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $419,200.00 in StockJune 12, 2025 | insidertrades.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. June 30 at 2:00 AM | Paradigm Press (Ad)ADMA Biologics, Inc. (NASDAQ:ADMA) Director Jerrold B. Grossman Sells 10,000 SharesJune 11, 2025 | insidertrades.comCantor Fitzgerald Comments on ADMA Biologics FY2025 EarningsJune 28 at 2:51 AM | americanbankingnews.comImplied Volatility Surging for ADMA Biologics Stock OptionsJune 27 at 8:26 PM | finance.yahoo.comADMA Biologics Inc Valuation - MorningstarJune 24, 2025 | morningstar.comMADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload PortfoliosJune 24, 2025 | msn.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $17.15 at the start of the year. Since then, ADMA shares have increased by 6.2% and is now trading at $18.21. View the best growth stocks for 2025 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, May, 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by $0.02. The company's revenue for the quarter was up 40.2% on a year-over-year basis. Read the conference call transcript. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2025Today6/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$27.67 High Stock Price Target$32.00 Low Stock Price Target$25.00 Potential Upside/Downside+51.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.85 Trailing P/E Ratio21.41 Forward P/E Ratio35.75 P/E GrowthN/ANet Income$197.67 million Net Margins45.01% Pretax Margin30.64% Return on Equity47.16% Return on Assets30.51% Debt Debt-to-Equity Ratio0.22 Current Ratio6.58 Quick Ratio3.36 Sales & Book Value Annual Sales$426.45 million Price / Sales10.21 Cash Flow$0.54 per share Price / Cash Flow33.55 Book Value$1.48 per share Price / Book12.32Miscellaneous Outstanding Shares238,730,000Free Float229,901,000Market Cap$4.35 billion OptionableOptionable Beta0.47 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:ADMA) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.